^
Association details:
Biomarker:EGFR T790M
Cancer:Non Small Cell Lung Cancer
Drug:APL-103 (EGFR inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

First-in-Human Phase 1 Study of ES-072, an Oral Mutant-Selective EGFR T790M Inhibitor, in Non-Small-Cell Lung Cancer

Published date:
07/09/2020
Excerpt:
This first-in-human phase 1 study evaluated the maximum tolerated dose, recommended phase 2 dose (RP2D), safety, tolerability, and pharmacokinetics (PK), and preliminarily determined the antitumor activity of ES-072 in NSCLC patients with EGFR T790M mutations....The total objective response rate and disease control rate were 46.2% and 76.9%, respectively.
DOI:
10.1016/j.cllc.2020.07.001